Eculizumab News
Eculizumab currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Eculizumab with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical...
- Evidence level: L5
- Predicted indications (20):
- cyclic hematopoiesis (100.0%)
- autosomal recessive severe congenital neutropenia due to JAGN1 deficiency (100.0%)
- X-linked severe congenital neutropenia (100.0%)
- congenital neutropenia-myelofibrosis-nephromegaly syndrome (100.0%)
- adult idiopathic neutropenia (100.0%)
- autosomal recessive severe congenital neutropenia due to CXCR2 deficiency (100.0%)
- primary immunodeficiency syndrome due to p14 deficiency (100.0%)
- autosomal recessive severe congenital neutropenia due to CSF3R deficiency (100.0%)
- severe congenital neutropenia (100.0%)
- primary release disorder of platelets (99.9%)
- pseudo-von Willebrand disease (99.9%)
- Barth syndrome (99.9%)
- Glanzmann thrombasthenia (99.9%)
- mixed-type autoimmune hemolytic anemia (99.9%)
- drug-induced autoimmune hemolytic anemia (99.9%)
- constitutional neutropenia (99.9%)
- primary CD59 deficiency (99.9%)
- cold agglutinin disease (99.9%)
- neonatal autoimmune hemolytic anemia (99.9%)
- autosomal recessive severe congenital neutropenia due to G6PC3 deficiency (99.9%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.